Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Last trade$14.80
Day change-$0.41 (-2.70%)
Day range$14.57 – $15.95
Volume471,561
Market cap$827M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$826.92M
Price / earnings
—
Price / book
2.06×
Price / sales
6.5×
EV / sales
5.86×
EV / EBITDA
-8.29×
Profitability
Earnings per share
-$1.53
Return on assets
-18.73%
Return on equity
-20.71%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.92×
Quick ratio
8.22×
Cash ratio
2.48×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.96M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BBNX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$35.51M
$32.01M
$27.63M
$32.12M
$27.25M
$23.24M
$17.64M
Cost of revenue
$15.17M
$13.11M
$11.19M
$13.18M
$12.13M
$10.74M
$8.67M
Gross profit
$20.33M
$18.9M
$16.44M
$18.94M
$15.12M
$12.5M
$8.97M
Selling, general and administrative
$34.97M
$34.24M
$30.35M
$24.94M
$23.97M
$23.5M
$20.02M
Research and development
$11.98M
$10.24M
$10.36M
$10.13M
$8.2M
$8.87M
$7.59M
Total operating expenses
$46.94M
$44.48M
$40.71M
$35.07M
$32.16M
$32.38M
$27.61M
Operating income
-$26.61M
-$25.58M
-$24.27M
-$16.12M
-$17.04M
-$19.87M
-$18.64M
Interest expense
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$24.35M
-$23.4M
-$21.9M
-$13.47M
-$14.21M
-$16.87M
-$28.66M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$24.35M
-$23.4M
-$21.9M
-$13.47M
-$14.21M
-$16.87M
-$28.66M
Net income attributable to common shareholders
-$24.35M
-$23.4M
-$21.9M
-$13.47M
-$14.21M
-$16.87M
-$28.66M
EBITDA
-$25.72M
-$24.87M
-$23.69M
-$15.59M
-$16.66M
-$19.53M
-$18.34M
Basic earnings per share
-$0.52
-$0.53
-$0.49
-$0.30
-$0.33
-$0.39
-$0.93
Diluted earnings per share
-$0.52
-$0.53
-$0.49
-$0.30
-$0.33
-$0.39
-$0.93
Recent news
Company coverage with links to the original publishers.
Beta Bio reported Q3 2026 net sales of $35.5 million with strong pharmacy channel momentum. The company received FDA clearance for Mint, its tubeless patch pump launching in Q1 2027, expected to drive significant growth. Management raised full-year 2026 revenue guidance and highlighted that Mint's gross margins could exceed current patch pump products within three years. The company is resubmitting its 3D Intelligence dosing algorithm application after addressing FDA feedback.
A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be entitled to compensation. The lead plaintiff deadline is November 3, 2026.
Beta Bionics, Inc. investors have until November 3, 2026 to request appointment as lead plaintiff in a securities fraud class action lawsuit. The complaint alleges the company failed to disclose material adverse facts regarding FDA Form 483 findings, including over 18,000 complaints and life-threatening hypoglycemic events that were not properly investigated or reported. The stock fell 37% on January 9, 2026 following disappointing preliminary fourth quarter 2025 financial results.
A class action lawsuit has been filed against Beta Bionics, Inc. alleging that the company made materially false and misleading statements regarding its iLet Bionic Pancreas insulin pump. The complaint claims the company failed to disclose FDA observations about quality management system deficiencies, device malfunctions, and unreported serious customer injuries. Investors who purchased Beta Bionics securities between July 30, 2025 and February 24, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 3, 2026.
A class action lawsuit has been filed against Beta Bionics, Inc. for making materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The company allegedly failed to implement meaningful corrective actions despite thousands of complaints. Investors who purchased shares between July 30, 2025 and February 24, 2026 have until November 3, 2026 to apply as lead plaintiff.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.